Bile Duct Cancer
Bile Duct Cancer
Katy MarshallBile Duct Cancer | July 3, 2024
The study's primary end point was overall survival.
Read More
Emily MenendezBile Duct Cancer | June 26, 2024
As gem/cis is linked to low survival times, various trials have attempted to improve first-line therapy outcomes for CCA.
Johnathan Ebben, MD, PhDBile Duct Cancer | June 12, 2024
Drs. Ebben and Uboha break down the importance of the QUIC study, a phase 2 investigation of first-line treatment of BTC.
Richard S. Finn, MDBile Duct Cancer | June 6, 2024
Richard Finn, MD, of University of California, Los Angeles, highlights 3-year follow-up data from KEYNOTE-966.
Katy MarshallBile Duct Cancer | June 3, 2024
Treatment-related adverse events were mostly sitravatinib related and included hand-foot syndrome and hypertension.
Emily MenendezBile Duct Cancer | May 31, 2024
A study investigated atezolizumab with varlilumab, an anti-CD27 human antibody, with or without cobimetinib, a MEK inhibitor.
Emily MenendezBile Duct Cancer | May 14, 2024
Determining which patients can benefit the most from immunotherapy remains elusive.
Emily MenendezBile Duct Cancer | April 23, 2024
TOPAZ-1's 3-year follow-up is the longest survival follow-up for a global, randomized phase III trial in this setting.
William Jarnagin, MD, FACSBile Duct Cancer | April 16, 2024
Dr. William Jarnagin discusses his recent study on characterizing the heterogeneity of intrahepatic cholangiocarcinoma.
Emily MenendezBile Duct Cancer | April 16, 2024
This approval marks the first tumor-agnostic approval of a HER2-directed therapy.
Ghassan Abou-Alfa, MDBile Duct Cancer | March 8, 2024
Dr. Abou-Alfa describes the promising outcomes of infigratinib and delves into further research on FGFR alterations in CCA.
Emily MenendezBile Duct Cancer | April 12, 2024
Patients who underwent targeted therapy for IDH1/2 alterations or FGFR2 fusions showed a 100% concordance rate.
Emily MenendezBile Duct Cancer | February 12, 2024
The developed nomogram was found to provide significant diagnostic accuracy with an area under the curve level of 0.882.
Emily MenendezASCO GI 2024 | February 7, 2024
Meta-analysis data has shown that HAIP combined with systemic chemotherapy can provide a pooled 3-year OS rate of 39.5%.
Amit Mahipal, MDASCO GI 2024 | January 31, 2024
Dr. Amit Mahipal discusses liquid biopsy for advanced cholangiocarcinoma and how it compares to tissue-based testing.
Milind Javle, MDASCO GI 2024 | January 25, 2024
Dr. Milind Javle discusses tinengotinib monotherapy in patients with metastatic cholangiocarcinoma at ASCO GI 2024.
Katy MarshallASCO GI 2024 | January 23, 2024
The most common first-line therapies were gemcitabine and cisplatin.
Katy MarshallASCO GI 2024 | January 23, 2024
The FDA approved futibatinib in 2022 for previously treated patients with advanced CCA and FGFR2 fusions or rearrangements.
Zachary BessetteASCO GI 2024 | January 23, 2024
New research sheds light on the prognostic value of mutations—including FGFR2 and IDH1—in patients with resectable CCA.
Rob DillardGI Cancer | January 12, 2024
Bile duct cancer treatments could be improved by tailored medications that target the levels of a key protein in ...
Latest News

July 18, 2024